🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prospective Cohort Study for Lymphoma: Samsung Lymphoma Cohort Study IV

Recruitingn/aAges any - anyAllSamsung Medical Center
NCT07032103 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This prospective study enrolls patients who are diagnosed with aggressive lymphoma including Hodgkin and non-Hodgkin lymphomas. Enrolled patients will be treated according to our institution' treatment policy in clinical practice. The disease status including response to therapy and survival status will be regularly updated during the study period. Patients' serum and cell-free DNA will be collected and analyzed.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Pathologically diagnosed Hodgkin and non-Hodgkin lymphomas 2. 20 years 3. Patients requiring systemic chemotherapy with curative intent 4. Written informed consent Exclusion Criteria: 1. Myeloid malignancy 2. Multiple myeloma 3. Patients do not require systemic chemotherapy with curative intent
💊

What it tests

  • Immunochemotherapy
📍

Where

1 site
Samsung Medical Center
Seoul, South Korea
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy